Chlorothiazide
Aldoclor, Chlorothiazide, Diupres, Diuril (chlorothiazide) is a small molecule pharmaceutical. Chlorothiazide was first approved as Diuril on 1982-01-01. It is used to treat edema, glomerulonephritis, heart failure, hypertension, and liver cirrhosis amongst others in the USA. The pharmaceutical is active against solute carrier family 12 member 3.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Chlorothiazide, Diuril (discontinued: Chlorothiazide, Diuril)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Chlorothiazide
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| DIURIL | Salix Pharmaceuticals | N-011870 RX | 1982-01-01 | 1 products, RLD, RS |
Show 1 discontinued
Chlorothiazide
+
Methyldopa
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ALDOCLOR-150 | Merck & Co | N-016016 DISCN | 1982-01-01 | 1 products |
| ALDOCLOR-250 | Merck & Co | N-016016 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Chlorothiazide
+
Reserpine
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| DIUPRES-250 | Merck & Co | N-011635 DISCN | 1987-08-26 | 1 products |
| DIUPRES-500 | Merck & Co | N-011635 DISCN | 1987-08-26 | 1 products |
Hide discontinued
Chlorothiazide sodium
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| DIURIL | Rising Pharmaceuticals | N-011145 DISCN | 1982-01-01 | 1 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| chlorothiazide | ANDA | 2025-03-20 |
| chlorothiazide sodium | ANDA | 2025-03-21 |
| diuril | New Drug Application | 2021-11-01 |
| sodium diuril | New Drug Application | 2022-07-01 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C03: Diuretics
— C03A: Low-ceiling diuretics, thiazides
— C03AA: Thiazides, plain
— C03AA04: Chlorothiazide
— C03AB: Thiazides and potassium in combination
— C03AB04: Chlorothiazide and potassium
— C03AH: Thiazides, combinations with psycholeptics and/or analgesics
— C03AH01: Chlorothiazide, combinations
HCPCS
Code | Description |
|---|---|
| J1205 | Injection, chlorothiazide sodium, per 500 mg |
Clinical
Clinical Trials
348 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | 14 | 14 | 81 | 100 | 34 | 241 |
| Essential hypertension | D000075222 | — | I10 | 3 | 4 | 28 | 9 | 4 | 46 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | 5 | 3 | 1 | 10 | 2 | 21 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 4 | 2 | 2 | 10 | 1 | 19 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | 1 | 1 | 3 | 7 | 2 | 14 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | 2 | — | — | 8 | — | 10 |
| Heart failure | D006333 | EFO_0003144 | I50 | 1 | — | 2 | 5 | 2 | 10 |
| Chronic renal insufficiency | D051436 | — | N18 | 1 | — | 1 | 5 | 2 | 9 |
| Isolated systolic hypertension | D000092244 | — | — | 1 | — | 2 | 4 | 1 | 8 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | 5 | 1 | 2 | 8 |
Show 42 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 27 | — | 1 | — | 8 | 36 |
| Nephrolithiasis | D053040 | — | N20.0 | — | 2 | 2 | — | 3 | 6 |
| Vascular diseases | D014652 | EFO_0004264 | I77 | — | — | 1 | — | 2 | 3 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | 2 | — | 1 | 3 |
| Atherosclerosis | D050197 | EFO_0003914 | I25.1 | — | — | 2 | — | — | 2 |
| Hypercholesterolemia | D006937 | — | — | — | — | 1 | — | — | 1 |
| Acute kidney injury | D058186 | — | N17 | — | — | 1 | — | — | 1 |
| Pregnancy-induced hypertension | D046110 | — | O13 | — | — | 1 | — | — | 1 |
| Pre-eclampsia | D011225 | EFO_0000668 | O14 | — | — | 1 | — | — | 1 |
| Eclampsia | D004461 | — | O15 | — | — | 1 | — | — | 1 |
Show 8 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypercalciuria | D053565 | — | R82.994 | — | 1 | — | — | 3 | 4 |
| Aging | D000375 | GO_0007568 | R41.81 | — | 2 | — | — | 1 | 3 |
| Hyperlipidemias | D006949 | EFO_0003774 | E78.5 | — | 1 | — | — | 1 | 2 |
| Critical illness | D016638 | — | — | — | 1 | — | — | 1 | 2 |
| Sedentary behavior | D057185 | — | — | — | 1 | — | — | — | 1 |
| Cognitive dysfunction | D060825 | — | G31.84 | — | 1 | — | — | — | 1 |
| Hypocalcemia | D006996 | HP_0002901 | E83.51 | — | 1 | — | — | — | 1 |
| Hypoparathyroidism | D007011 | — | E20 | — | 1 | — | — | — | 1 |
| Hypernatremia | D006955 | — | E87.0 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | 2 | — | — | — | 2 | 4 |
| Therapeutic equivalency | D013810 | — | — | 2 | — | — | — | — | 2 |
| Fasting | D005215 | EFO_0002756 | — | 2 | — | — | — | — | 2 |
| Endocrine system diseases | D004700 | EFO_0001379 | E34.9 | 1 | — | — | — | 1 | 2 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | 2 | — | — | — | — | 2 |
| Pure autonomic failure | D054970 | — | — | 1 | — | — | — | — | 1 |
| Drug interactions | D004347 | — | — | 1 | — | — | — | — | 1 |
| Chronic pain | D059350 | — | — | 1 | — | — | — | — | 1 |
| Photosensitivity disorders | D010787 | — | L57.1 | 1 | — | — | — | — | 1 |
| Vascular stiffness | D059289 | — | — | 1 | — | — | — | — | 1 |
Show 1 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Disease | D004194 | EFO_0000408 | R69 | — | — | — | — | 2 | 2 |
| Bone diseases | D001847 | — | M89.9 | — | — | — | — | 1 | 1 |
| Hyperparathyroidism | D006961 | EFO_0008506 | E21.3 | — | — | — | — | 1 | 1 |
| Secondary hyperparathyroidism | D006962 | EFO_1001173 | — | — | — | — | — | 1 | 1 |
| Skin neoplasms | D012878 | EFO_0004198 | C44 | — | — | — | — | 1 | 1 |
| Melanoma | D008545 | — | — | — | — | — | — | 1 | 1 |
| Morbid obesity | D009767 | EFO_0001074 | — | — | — | — | — | 1 | 1 |
| Critical care | D003422 | — | — | — | — | — | — | 1 | 1 |
| Fluid shifts | D018495 | — | — | — | — | — | — | 1 | 1 |
| Calculi | D002137 | — | — | — | — | — | — | 1 | 1 |
Show 6 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Chlorothiazide |
| INN | chlorothiazide |
| Description | Chlorothiazide is 4H-1,2,4-benzothiadiazine 1,1-dioxide in which the hydrogen at position is substituted by chlorine and that at position 7 is substituted by a sulfonamide group. A diuretic, it is used for treatment of oedema and hypertension. It has a role as a diuretic and an antihypertensive agent. |
| Classification | Small molecule |
| Drug class | diuretics (thiazide derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | NS(=O)(=O)c1cc2c(cc1Cl)N=CNS2(=O)=O |
Identifiers
| PDB | — |
| CAS-ID | 58-94-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL842 |
| ChEBI ID | 3640 |
| PubChem CID | 2720 |
| DrugBank | DB00880 |
| UNII ID | 77W477J15H (ChemIDplus, GSRS) |
Target
Agency Approved
SLC12A3
SLC12A3
Organism
Homo sapiens
Gene name
SLC12A3
Gene synonyms
NCC, TSC
NCBI Gene ID
Protein name
solute carrier family 12 member 3
Protein synonyms
Na-Cl cotransporter, Na-Cl symporter, NaCl electroneutral thiazide-sensitive cotransporter, NCC, sodium-chloride co-transporter, solute carrier family 12 (sodium/chloride transporter), member 3, thiazide-sensitive Na-Cl cotransporter, Thiazide-sensitive sodium-chloride cotransporter
Uniprot ID
Mouse ortholog
Slc12a3 (20497)
solute carrier family 12 member 3 (P59158)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Chlorothiazide
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Chlorothiazide
+
Methyldopa
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,521 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
64,615 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use